Advertisement rdharma@digitalinsightresearch.in, Author at Pharmaceutical Business review - Page 44 of 56
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Pfizer gets FDA nod for lung cancer drug Lorbrena

Lorbrena is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to treat patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least

Cipher launches Brinavess antiarrhythmic drug in Canada

AF affects approximately 350,000 patients in Canada. St. Michael’s Hospital staff cardiac electrophysiologist and University of Toronto cardiology division department director Dr Paul Dorian said: “Brinavess offers an important

FDA approves Roche’s Xofluza to treat influenza

Xofluza is a first-in-class and single-dose oral medicine with a novel proposed mechanism of action, which restricts polymerase acidic endonuclease, an enzyme required for viral replication. According to